A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, VEHICLE-CONTROLLED, FIRST-IN-HUMAN, MULTIPLE-DOSE STUDY, TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS, OF TOPICALLY ADMINISTERED PF-07295324 AND PF-07259955, IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 16 Nov 2024
At a glance
- Drugs PF 07259955 (Primary) ; PF 07295324 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors Pfizer
Most Recent Events
- 09 Sep 2022 Status changed from active, no longer recruiting to completed.
- 03 Aug 2022 Planned End Date changed from 29 Jul 2022 to 12 Aug 2022.
- 03 Aug 2022 Planned primary completion date changed from 29 Jul 2022 to 12 Aug 2022.